Is higher trimethylamine N-oxide linked to cardiovascular risk?

Higher circulating trimethylamine N-oxide (TMAO), a gut microbiome–diet–host metabolite, is a clinically relevant cardiovascular risk marker. The evidence supports an association with adverse cardiovascular outcomes, while its direct causal role in human vascular disease remains uncertain.

Clinical evidence

• Across 11 prospective cohorts, higher TMAO was associated with cardiovascular events (pooled HR 1.23, 95% CI 1.07–1.42). A 44-cohort synthesis found higher cardiovascular mortality (RR 1.51, 95% CI 1.23–1.87), although certainty was rated low to very low.
• In older adults with established atherosclerotic cardiovascular disease, the highest TMAO category predicted recurrent events (HR 1.25, 95% CI 1.01–1.56).
• Kidney function is pivotal: associations weaken or become nonsignificant after eGFR adjustment in some older-adult and acute-coronary-syndrome cohorts. Because TMAO is predominantly renally cleared, elevation may reflect reduced filtration and correlated cardiometabolic risk as well as, potentially, a contributing pathway.

Mechanistic evidence

• Experimental endothelial models show TMAO activation of NF-κB/MAPK signaling, increased ICAM-1, VCAM-1, E-selectin, IL-6, and COX-2, and mitochondrial oxidative-stress–dependent NLRP3 activation with IL-1β/IL-18 signaling and barrier dysfunction.
• In mice, TMAO increases macrophage CD36/SR-A1 expression, oxidized-LDL uptake, and foam-cell formation. It reduced macrophage-to-liver reverse cholesterol transport by approximately 35%.
• Oxidative stress can reduce eNOS activation, scavenge nitric oxide through superoxide, and impair endothelium-dependent vasodilation.

Interpretation

• Human plaque-imaging findings are mixed, and experimental inflammatory effects depend on dose, exposure duration, and model; some in-vitro concentrations may not reflect typical human exposure.

Bottom line

• For a 71-year-old man, elevated TMAO should be viewed as a risk-associated biomarker rather than a proven treatment target. Its links to vascular inflammation and atherosclerosis are mechanistically credible and strongly supported in preclinical models, but lowering TMAO itself has not been shown to improve cardiovascular outcomes.